About annexon inc - ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
ANNX At a Glance
Annexon, Inc.
1400 Sierra Point Parkway
Brisbane, California 94005
| Phone | 1-650-822-5500 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -206,690,000.00 | |
| Sector | Health Technology | Employees | 96 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ANNX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.543 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.663 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.046 |
ANNX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,153,020.833 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ANNX Liquidity
| Current Ratio | 5.681 |
| Quick Ratio | 5.681 |
| Cash Ratio | 5.591 |
ANNX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -65.862 |
| Return on Equity | -81.897 |
| Return on Total Capital | -86.90 |
| Return on Invested Capital | -74.55 |
ANNX Capital Structure
| Total Debt to Total Equity | 12.38 |
| Total Debt to Total Capital | 11.016 |
| Total Debt to Total Assets | 9.439 |
| Long-Term Debt to Equity | 11.006 |
| Long-Term Debt to Total Capital | 9.793 |